JWCTF (JW (Cayman) Therapeutics Co) ROCE %: -73.46% (As of Dec. 2025)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
30 GF Score
Price $0.24
GF Value $0.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co ROCE %?

JW (Cayman) Therapeutics Co JWCTF 30 ROCE % is -73.46% as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 30/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. JW (Cayman) Therapeutics Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -73.46%.

JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

JW (Cayman) Therapeutics Co ROCE % Related Terms

JW (Cayman) Therapeutics Co ROCE % Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co ROCE % Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -21.97 -29.58 -34.17 -36.91 -61.17

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.45 -26.26 -47.84 -48.62 -73.46
JWCTF
30GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co ROCE % Calculation

JW (Cayman) Therapeutics Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-76.782/( ( (230.797 - 63.875) + (140.12 - 55.996) )/ 2 )
=-76.782/( (166.922+84.124)/ 2 )
=-76.782/125.523
=-61.17 %

JW (Cayman) Therapeutics Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-79.444/( ( (197.683 - 65.505) + (140.12 - 55.996) )/ 2 )
=-79.444/( ( 132.178 + 84.124 )/ 2 )
=-79.444/108.151
=-73.46 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -73.46% mean?
JW (Cayman) Therapeutics Co (JWCTF) has a ROCE % of -73.46% as of Dec. 2025.
Is JW (Cayman) Therapeutics Co's ROCE % too high?
JW (Cayman) Therapeutics Co's current ROCE % is -73.46%. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's ROCE % compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's ROCE % of -73.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. JW (Cayman) Therapeutics Co's current ROCE % is -73.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.24 — trading 58.3% below its estimated fair value. The current ROCE % is -73.46%. JW (Cayman) Therapeutics Co's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current ROCE % is -73.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.24 is trading 58.3% below its estimated GF Value™ of $0.57. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • ROCE %: -73.46%
  • GF Value™: $0.57 vs. price of $0.24 (58.3% below fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
30GF Score

Get the complete analysis for JWCTF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price
$0.57
GF Value